FrancophonIA/ELRC3.0 huggingface dataset:
English: The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight).
Slovenian: Brizgalka se prilega na stekleničko in ima merilno skalo z oznakami telesne mase v kilogramih, ki ustrezajo vzdrževalnemu odmerku (0,1 mg meloksikama na kilogram telesne mase).
English: Route and method of administration
Slovenian: Odmerjanje in pot uporabe
English: By pushing the plunger in empty the contents of the syringe onto the food.
Slovenian: Pritisnite na bat in spraznite vsebino brizgalke na hrano.
English: The treatment-free period, however, should take into account the pharmacological properties of veterinary medicinal products used previously.
Slovenian: Poleg tega je treba pri določanju obdobja brez zdravil upoštevati farmakološke lastnosti zdravil, ki smo jih dajali predhodno.
English: People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Slovenian: Osebe, preobčutljive na nesteroidna protivnetna zdravila (NSAR), se morajo izogibati stiku z veterinarskim zdravilom.
English: Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.
Slovenian: Začetni odmerek na prvi dan zdravljenja je 0,2 mg meloksikama na kilogram telesne mase.
English: Name and address of the manufacturer(s) responsible for batch release
Slovenian: Ime in naslov izdelovalca(izdelovalcev) zdravila, odgovornega za sproščanje serij
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One ml contains:
Slovenian: NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGEIH SESTAVIN En ml vsebuje:
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carton box for bottle 10 and 30 ml
Slovenian: PODATKI NA ZUNANJI OVOJNINI Kartonska škatla za stekleničko 10 in 30 ml
English: Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Slovenian: Občasno so poročali o značilnih neželenih učinkih nesteroidnih protivnetnih zdravil, kot so izguba teka, bruhanje, driska, kri v blatu (okultna krvavitev), letargija in ledvična odpoved.
English: There is a linear relationship between the dose of meloxicam administered and plasma concentration observed in the therapeutic dose range.
Slovenian: Pri terapevtskem razponu odmerkov je med vnesenim odmerkom in koncentracijo v plazmi linearno razmerje.
English: Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Slovenian: Ne uporabljajte pri psih, ki imajo gastrointestinalne motnje, kot sta iritacija in krvavitev, oslabljeno delovanje jeter, srca ali ledvic ter motnje v strjevanju krvi.
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) Meloxicam 0.5 mg/ml
Slovenian: KOLIČINA ZDRAVILNE(IH) UČINKOVIN(E) Meloksikam 0,5 mg/ml
English: INDICATION(S) Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Slovenian: INDIKACIJA(E) Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri psih.
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) Meloxicam 1.5 mg/ml
Slovenian: KOLIČINA ZDRAVILNE(IH) UČINKOVIN(E) Meloksikam 1,5 mg/ml
English: Once opened, use within 6 months.
Slovenian: Načeto zdravilo uporabite v 6-ih mesecih.
English: Shelf life after first opening the immediate packaging: 6 months.
Slovenian: Rok uporabnosti zdravila v pakiranju za prodajo: 3 leta Rok uporabnosti po prvem odpiranju neposredne ovojnine: 6 mesecev.
English: Treatment is to be continued once daily by oral administration (24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
Slovenian: Zdravljenje nadaljujemo s peroralnim, vzdrževalnim odmerkom (v 24 urnih intervalih) 0,1 mg meloksikama na kilogram telesne mase, ki se odmeri enkrat dnevno.
English: ROUTE(S) OF ADMINISTRATION Oral use.
Slovenian: POT(I) UPORABE ZDRAVILA Peroralna uporaba.
English: C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
Slovenian: C. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE VARNE IN UČINKOVITE UPORABE
English: Date of last renewal:
Slovenian: Datum podaljšanja dovoljenja za promet:
English: The suspension has to be given with the measuring syringes provided in the package of the 30 ml and 150 ml pack size or with one of the two measuring syringes provided in the package of the 10 ml pack size.
Slovenian: Suspenzijo je treba odmeriti z odmerno brizgalko, ki je sestavni del pakiranja po 30 ml ali 150 ml ali z eno od veh odmernih brizgalk, ki sta na voljo v pakiranju po 10 ml. Brizgalka se prilega na stekleničko in ima merilno skalo z oznakami telesne mase v kilogramih, ki ustrezajo vzdrževalnemu odmerku (0,1 mg meloksikama na kilogram telesne mase).
English: SPECIAL STORAGE CONDITIONS This veterinary medicinal product does not require any special storage conditions.
Slovenian: POSEBNA NAVODILA ZA SHRANJEVANJE Za shranjevanje ni posebnih navodil.
English: A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Slovenian: A. IMETNIK(I) DOVOLJENJ(A) ZA IZDELAVO ZDRAVILA, ODGOVOREN(ODGOVORNI) ZA SPROŠČANJE SERIJE
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Label bottle 150 ml
Slovenian: PODATKI NA STIČNI OZ. PRIMARNI OVOJNINI Z nalepko označiti stekleničke po 150 ml
English: Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Slovenian: 6.6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
English: Turn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle.
Slovenian: Stekleničko zopet obrnite navzgor, nato odstranite brizgalko.
English: Do not administer Meloxivet: - if your dog is pregnant or during lactation - if your dog is suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders - if your dog is hypersensitive (allergic) to the active substance or to any of the other ingredients.
Slovenian: Zdravila Meloxivet ne smete dajati: - med brejostjo ali laktacijo, - če ima vaš pes gastrointestinalne motnje kot sta iritacija in krvavitev, oslabljeno delovanje jeter,
English: Push down and unscrew bottle top.
Slovenian: Zaporko potisnite navzdol in jo odvijte.
English: Attach the dosing syringe to the bottle by gently pushing the end onto the top the bottle
Slovenian: Na stekleničko pritrdite odmerno brizgalko, tako da jo nanjo previdno pritisnete.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/07/077/005
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/07/077/005
English: MARKETING AUTHORISATION NUMBER(S) EU/2/07/077/001
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/07/077/001
English: 30 ml and 150 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and clear polypropylene dosing syringe.
Slovenian: 30 ml in 150 ml različici: rjava steklena steklenička (tip III) s polipropilensko, za otroke varno zaporko, polietilenskim zamaškom in prozorno polipropilensko odmerno brizgalko.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxivet 0.5 mg/ml oral suspension for dogs
Slovenian: IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Meloxivet 0,5 mg/ml, peroralna suspenzija za pse
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxivet 1.5 mg/ml oral suspension for dogs
Slovenian: IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Meloxivet 1,5 mg/ml, peroralna suspenzija za pse
English: MARKETING AUTHORISATION NUMBER(S) EU/2/07/077/003
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/07/077/003
English: PACKAGE LEAFLET FOR: Meloxivet 1.5 mg/ml oral suspension for dogs
Slovenian: NAVODILO ZA UPORABO Meloxivet 1,5 mg/ml, peroralna suspenzija za pse
English: PACKAGE LEAFLET FOR: Meloxivet 0.5 mg/ml oral suspension for dogs
Slovenian: NAVODILO ZA UPORABO Meloxivet 0,5 mg/ml, peroralna suspenzija za pse
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Label bottle 10 and 30 ml
Slovenian: Z nalepko označiti stekleničke po 10 in 30 ml
English: 30 ml: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and amber polypropylene dosing syringe.
Slovenian: 30 ml: rjava steklena steklenička (tip III) s polipropilensko, za otroke varno zaporko, polietilenskim zamaškom in rumeno rjavo polipropilensko odmerno brizgalko.
English: 10 ml: amber glass bottle (type III) with polyethylene child resistant closure, polyethylene insert and amber polypropylene dosing syringe.
Slovenian: 10 ml: rjava steklena steklenička (tip III) s polietilensko, za otroke varno zaporko, polietilenskim zamaškom in rumeno rjavo polipropilensko odmerno brizgalko.
English: 30 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and an amber polypropylene dosing syringe.
Slovenian: 30 ml različica: rjava steklena steklenička (tip III) s polipropilensko, za otroke varno zaporko, polietilenskim zamaškom in rumeno rjavo polipropilensko odmerno brizgalko.
English: Excipient: Sodium benzoate
Slovenian: Pomožna (e) snov (i) Natrijev benzoat
English: 10 ml presentation: amber glass bottle (type III) with polyethylene child resistant closure, polyethylene insert and clear polypropylene dosing syringe.
Slovenian: 10 ml različica: rjava steklena steklenička (tip III) s polietilensko, za otroke varno zaporko, polietilenskim zamaškom in dvema prozornima polipropilenskima odmernima brizgalkama.
English: 10 ml presentation: amber glass bottle (type III) with polyethylene child resistant closure, polyethylene insert and an amber polypropylenedosing syringe.
Slovenian: 10 ml različica: rjava steklena steklenička (tip III) s polietilensko, za otroke varno zaporko, polietilenskim zamaškom in priloženima dvema prozornima polipropilenskima brizgalkama.
English: Glycerol
Slovenian: 4.11 Karenca
English: 1 Article 29(4) of Directive 2001/83/EC, as amended.
Slovenian: 1 Člen 29(4) of Direktive 2001/83/ES, kakor je bila spremenjena.
English: The Reference Member State was Czech Republic and the Concerned Member States were Austria, Denmark, Germany, Estonia, Greece, France, Hungary, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Sweden, Slovenia, Slovak Republic and the United Kingdom.
Slovenian: Referenčna država članica je bila Češka republika, zadevne države članice pa so bile Avstrija, Danska, Nemčija, Estonija, Grčija, Francija, Madžarska, Italija, Latvija, Litva, Nizozemska, Norveška, Poljska, Portugalska, Švedska, Slovenija, Slovaška republika in Združeno kraljestvo.
English: The Rapporteur was Dr Ondrej Slanar and Co-Rapporteur was Dr Matthew Thatcher.
Slovenian: Poročevalec je bil dr. Ondrej Slanar, soporočevalec pa dr. Matthew Thatcher.
English: The final opinion was converted into a Decision by the European Commission on 22 November 2007.
Slovenian: Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 22. novembra 2007.
English: The Mutual Recognition Procedure started on 21 September 2006.
Slovenian: Postopek medsebojnega priznavanja se je začel 21. septembra 2006.
English: Czech Republic referred the reasons for disagreement to the EMEA on 30 March 2007.
Slovenian: Češka republika je agenciji EMEA posredovala razloge za nesoglasje dne 30. marca 2007.
English: A positive opinion was adopted by consensus on 20 September
Slovenian: Pozitivno mnenje je bilo soglasno sprejeto dne 20. septembra 2007.
English: Significant differences have been identified with regard to the benefit/risk ratio of the product.
Slovenian: V zvezi z razmerjem med koristmi in tveganji zdravila so bile ugotovljene znatne razlike.
English: The Marketing Authorisation Holder provided written explanations on 20 July 2007.
Slovenian: Imetnik dovoljenja za promet z zdravilom je podal pisna pojasnila 20. julija 2007.
English: The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III.
Slovenian: Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, Povzetek glavnih značilnosti zdravila pa v Dodatku III.
English: This refers to two indications (treatment of locally advanced prostatic carcinoma without metastases, for which surgical castration or other type of medical intervention is not indicated or unacceptable; and as monotherapy in early treatment or as an adjunct to treatment with radiotherapy or radical prostatectomy in patients with prostatic carcinoma (T3-T4, any Stage N, M0) and this was considered to be of serious public health concern.
Slovenian: Te se nanašajo na dve indikaciji (zdravljenje lokalno napredovalega karcinoma prostate brez metastaz, pri katerem kirurška kastracija ali druga vrsta zdravstvenega posega ni indicirana ali sprejemljiva, ter kot monoterapija pri zgodnjem zdravljenju ali kot dopolnilo k zdravljenju z obsevanjem ali radikalno prostatektomijo pri bolnikih s karcinomom prostate (T3-T4, katerikoli stadij N, M0)) in predstavljajo resen zadržek glede javnega zdravja.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR Bicaluplex and associated names International Non-Proprietary Name (INN): bicalutamide
Slovenian: ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 29(4)1 ZA Bicaluplex in z njim povezana imena Mednarodno nelastniško ime (INN): bikalutamid
English: During their September 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Bicaluplex and associated names, that the objections raised by Germany should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Slovenian: Med svojim zasedanjem septembra 2007 je CHMP na podlagi vseh posredovanih podatkov in znanstvene razprave v okviru Odbora, sprejel mnenje, da je razmerje med koristmi in tveganji za zdravilo Bicaluplex in z njim povezana imena ugodno, ter da ugovori, ki jih je podala Nemčija, ne bi smeli preprečiti podelitve dovoljenja za promet z zdravilom, ter da je treba Povzetek glavnih značilnosti zdravila, označevanje in Navodilo za uporabo referenčne države članice dopolniti.
English: Bicaluplex and associated names, 150 mg, film-coated tablet, is an oral anti-androgen used in the management of prostate cancer.
Slovenian: Bicaluplex in z njim povezana imena, 150 mg, filmsko obložene tablete, je peroralni antiandrogen, ki se uporablja za zdravljenje raka na prostati.
English: Ingers Industrials Solutions s.r.o submitted applications for mutual recognition of Bicaluplex and associated names, 150 mg, film-coated tablet on the basis of the marketing authorisation granted by Czech Republic on 30 November 2005.
Slovenian: Podjetje Ingers Industrials Solutions s.r.o je predložilo vloge za medsebojno priznavanje zdravila Bicaluplex in z njim povezanih imen, 150 mg, filmsko obložene tablete na osnovi dovoljenja za promet z zdravilom, ki ga je odobrila Češka republika dne 30. novembra 2005.
English: Pack size bottle (HDPE) 30 tablets bottle (HDPE) 90 (3 x 30) tablets
Slovenian: Farmacevtska oblika Pot uporabe Stična ovojnina Velikost pakiranja filmsko obložena tableta peroralna uporaba plastenka (HDPE) 30 tablet filmsko obložena tableta peroralna uporaba plastenka (HDPE) 90 (3 x 30) tablet
English: Route of Administration
Slovenian: Številka (EU) dovoljenja za promet
English: 20148 Milan
Slovenian: 20148 Milano
English: • a more frequent need to pass water, even at night.
Slovenian: • pogostejša potreba po odvajanju vode, celo ponoči.
English: 03410 Saint Victor France
Slovenian: 03410 Saint Victor Francija
English: Tell your doctor in particular, if you take:
Slovenian: Še zlasti povejte svojemu zdravniku, če jemljete:
English: The absolute bioavailability is approximately 32%.
Slovenian: Absolutna biološka uporabnost je približno 32%.
English: It does not distribute into blood cells.
Slovenian: Ne prehaja v krvne celice.
English: Do not give this medicine to children and adolescents below 18 years since there is no relevant indication for this age group.
Slovenian: Tega zdravila ne dajajte otrokom in mladostnikom, mlajšim od 18 let, ker v tej starostni skupini ni ustrezne indikacije.
English: This makes it easier for you to pass water and relieves your symptoms.
Slovenian: S tem olajša odvajanje vode in ublaži vaše simptome.
English: • Fainting/ Loss of consciousness
Slovenian: • omedlevica/izguba zavesti
English: • Difficulties in getting or keeping an erection
Slovenian: • težave pri doseganju in ohranjanju erekcije
English: This change is clinically not relevant and no dose adjustment is required.
Slovenian: Ta sprememba klinično ni pomembna in prilagoditev odmerka ni potrebna.
English: The expiry date refers to the last day of that month.
Slovenian: Rok uporabnosti zdravila se izteèe na zadnji dan navedenega meseca.
English: Food decreases Cmax by approximately 30%, increases tmax by approximately 1 hour and has little effect on AUC.
Slovenian: Hrana zniža Cmax za približno 30%, podaljša tmax za približno 1 uro in ima le majhen vpliv na AUC.
English: * p < 0.001 vs Placebo; ° p = 0.002 vs Placebo
Slovenian: * p < 0,001 v primerjavi s placebom; p = 0,002 v primerjavi s placebom
English: Take the capsule always with food, preferably at the same time every day.
Slovenian: Kapsulo vedno vzemite s hrano, najbolje vsak dan ob istem času.
English: Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Slovenian: Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke !
English: The capsule should be taken with food, preferably at the same time every day.
Slovenian: Kapsulo je treba vzeti s hrano, najbolje vsak dan ob istem času.
English: If this occurs, make sure you sit or lie down straight away until the symptoms have disappeared and inform your doctor as soon as possible (see also section “Driving and using machines”).
Slovenian: Če pride do tega, takoj sedite ali lezite, dokler simptomi ne izginejo in čimprej obvestite svojega zdravnika (glejte poglavje »Vpliv na sposobnost upravljanja vozil in strojev«).
English: The observed effect was reversible.
Slovenian: Opaženi učinek je bil reverzibilen.
English: Contact your doctor immediately if you notice any of the following allergic reactions: swelling of the face or throat, difficulty in breathing, feeling faint, itchy skin or hives since the consequences could become serious.
Slovenian: Takoj se posvetujte z zdravnikom, če opazite katere od naslednjih alergijskih reakcij: oteklost obraza ali žrela, težave z dihanjem, omotičnost, srbeča koža ali koprivnica, saj lahko njihove posledice postanejo resne.
English: • a feeling of not completely emptying the bladder,
Slovenian: • občutek, da mehur ni popolnoma izpraznjen
English: Baseline value (± SD)
Slovenian: Izhodiščna vrednost ( ± SD)
English: Packs of 10, 20, 30, 50, 90, 100 capsules.
Slovenian: Pakiranja po 10, 20, 30, 50, 90, 100 kapsul.
English: In total, 1,581 patients have received silodosin at a dose of 8 mg once daily, including 961 patients exposed for at least 6 months and 384 patients exposed for 1 year.
Slovenian: Skupno je 1.581 bolnikov prejemalo silodozin v odmerku 8 mg enkrat na dan, vključno z 961 bolniki, ki so bili zdravilu izpostavljeni najmanj 6 mesecev in 384 bolniki, ki so bili zdravilu izpostavljeni 1 leto.
English: It is reversible within a few days upon discontinuation of treatment (see section 4.4).
Slovenian: Učinek je reverzibilen v nekaj dneh po prekinitvi zdravljenja (glejte poglavje 4.4).
English: Do not use this medicine if you notice that is damaged or shows signs of tampering.
Slovenian: Ne uporabljajte tega zdravila, če opazite, da je pakiranje poškodovano ali kaže znake nepooblaščenega odpiranja.
English: The possible side effects are listed below:
Slovenian: Spodaj so navedeni možni neželeni učinki:
English: Minimal pharmacodynamic interactions have been observed between silodosin and maximum doses of sildenafil or tadalafil.
Slovenian: Minimalne farmakodinamske interakcije so opazili med silodozinom in največjimi odmerki sildenafila ali tadalafila.
English: 1 - adverse reactions from spontaneous reporting in the worldwide post-marketing experience (frequencies calculated from events reported in Phase I-IV clinical trials and non-interventional studies).
Slovenian: 1 - neželeni učinki iz spontanih poročil iz globalnih izkušenj po začetku trženja (pogostnosti so izračunane iz dogodkov, o katerih so poročali iz kliničnih preskušanj Faze I-IV in neintervencijskih študij).
English: • Decreased sexual drive
Slovenian: • zmanjšana želja po spolnosti
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation:
Slovenian: Datum prve odobritve: Datum zadnjega podaljšanja:
English: In vitro data indicate that silodosin does not have the potential to inhibit or induce cytochrome P450 enzyme systems.
Slovenian: In vitro podatki kažejo, da silodozin nima potenciala za zaviranje ali vzpodbujanje citokrom P450 encimskih sistemov.
English: Silodosin Placebo
Slovenian: silodozin placebo
English: Positive orthostatic tests were only slightly more common during co-administration; however, no symptomatic orthostasis or dizziness occurred.
Slovenian: Pozitivni ortostatski testi so bili ob sočasni uporabi le nekoliko bolj pogosti, vendar ni prišlo do simptomatske ortostaze ali omotičnosti.
English: Before starting treatment, the patient should be informed that this effect may occur, temporarily affecting male fertility.
Slovenian: Pred pričetkom zdravljenja je treba bolnika opozoriti, da lahko pride do tega učinka, ki začasno lahko prizadene moško plodnost.
English: Consequently, the concomitant use of other α-adrenoreceptor antagonists is not recommended.
Slovenian: Zaradi tega sočasna uporaba drugih antagonistov α-adrenergičnih receptorjev ni priporočljiva.
English: The terminal half-life of parent drug and its glucuronide is approximately 11 hours and 18 hours, respectively.
Slovenian: Končna razpolovna doba izhodiščne spojine in njenega glukuronida znaša približno 11 oziroma 18 ur.
English: If you do feel weak or dizzy, make sure you sit or lie down straight away until the symptoms have disappeared.
Slovenian: Če občutite šibkost ali omotico, takoj sedite ali lezite, dokler simptomi ne izginejo.
English: Difference (95% CI) vs placebo
Slovenian: Razlika (95% CI) v primerjavi s placebom
English: • difficulty in starting to pass water,
Slovenian: • težaven začetek odvajanja vode
English: The specialist can take appropriate precautions with respect to medicine and surgical techniques to be used.
Slovenian: Zdravnik specialist bo tako z ozirom na zdravilo in uporabljene kirurške tehnike lahko izpeljal posebne previdnostne ukrepe.
English: Exposure to silodosin and its main metabolites does not change significantly with age, even in subjects of age over 75 years.
Slovenian: Izpostavitev silodozinu in njegovim glavnim presnovkom se celo pri bolnikih, ki so starejši od 75 let, s starostjo bistveno ne spreminja.
English: It has been demonstrated in vitro that the α1A:α1B binding ratio of silodosin (162:1) is extremely high.
Slovenian: In vitro je bilo dokazano, da je α1A:α1B vezavno razmerje silodozina (162:1)
English: This may temporarily affect male fertility.
Slovenian: Ta učinek lahko začasno prizadene moško plodnost.